On Monday, the acting director of the Centers for Disease Control and Prevention (CDC) backed President Trump’s suggestion to separate the measles, mumps, and rubella (MMR) vaccine, even though there is no research supporting such significant changes.
In a post on Social Platform x, Jim O’Neill stated, “I’m urging vaccine manufacturers to create a safe, single vaccine that combines MMR and to break up the multiple MMR shots into three distinct ones.” He also advised pregnant women against taking Tylenol and suggested delaying the hepatitis B vaccine until children are at least 12 years old. It’s worth noting that O’Neill didn’t provide any reasons to believe that isolating the shots would be beneficial, but his remarks reflect the administration’s general skepticism towards vaccines.
O’Neill’s announcement followed a recommendation from a vaccine advisory panel that the CDC will offer a separate chicken pox vaccine, rather than combining it with the MMR vaccinations for toddlers.
The MMR vaccine, which received licensing back in 1971, phased out the individual shots in 2009 due to the success of the combined vaccine.
The American Academy of Pediatrics warns that isolating the vaccine components would lead to unnecessary delays, leaving children vulnerable to severe, life-threatening illnesses for longer periods.
Experts argue that separating the shots doesn’t make sense, especially amid rising vaccine skepticism. Currently, children are recommended to receive two MMR shots: the first between 12 to 15 months and the second at 4 to 6 years. If the shots are split, children would require six separate vaccinations instead.
William Schaffner, an epidemiologist and public policy professor at Vanderbilt University, commented, “We’ve seen a lot of people struggling in this context.” He also pointed out that each vaccination visit incurs additional charges, which can increase overall costs.
Schaffner noted, “This would escalate the costs of the vaccination program without yielding profits. In fact, we might predict that we’ll miss more vaccine appointments as we go east to west.” He emphasized how significant it was to successfully combine the vaccines in the first place.
Furthermore, the task of developing the separate vaccines represents a substantial logistical challenge for pharmaceutical companies, which currently doesn’t exist in the United States.
Since vaccines are classified as new products, they must go through a lengthy review process. This essentially means companies will need to readjust their product planning, conduct clinical trials, and then seek Food and Drug Administration approval, a process that can take years.
Separating the shots could disrupt pediatric practices and financially burden healthcare providers. Instead of administering a single vaccine, pediatricians would have to manage three separate vaccines and meticulously track individual shots for each patient.
